Details for New Drug Application (NDA): 062170
✉ Email this page to a colleague
NDA 062170 describes KLEBCIL, which is a drug marketed by King Pharms and is included in one NDA. Additional details are available on the KLEBCIL profile page.
The generic ingredient in KLEBCIL is kanamycin sulfate. There are five drug master file entries for this compound. Additional details are available on the kanamycin sulfate profile page.
The generic ingredient in KLEBCIL is kanamycin sulfate. There are five drug master file entries for this compound. Additional details are available on the kanamycin sulfate profile page.
Summary for 062170
| Tradename: | KLEBCIL |
| Applicant: | King Pharms |
| Ingredient: | kanamycin sulfate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 062170
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 75MG BASE/2ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 500MG BASE/2ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/3ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
